肿瘤中心早期乳腺癌辅助治疗10年回顾性分析

发布时间：2018-08-17 16:38

【摘要】：目的:收集吉林大学第一医院肿瘤中心2007年1月至2016年12月收治所有早期乳腺癌患者基本信息、病理情况、手术资料、治疗经过及预后随访等信息,回顾性分析我中心10年内患者情况变化、治疗方案变迁及预后分析,计算总体DFS及OS,与国内外水平对比,分析存在差异原因。分析不同分子分型患者间发病特征、病理特点及预后差异,同时,对比使用不同化疗方案患者的疾病特征。方法:收集吉林大学第一医院肿瘤中心2007年1月至2016年12月收治所有早期乳腺癌患者,依据入排标准共纳入2465例早期乳腺癌患者,对他们的疾病基本信息、治疗经过及预后等情况进行回顾性分析。了解不同分子分型的患者发病年龄、病理特点及预后的差异;接受不同化疗方案患者的疾病特征;所有出现复发转移患者的疾病特征。结果:1、对于具有完整随访资料的1990例患者,统计出3年、5年、7年DFS分别为86.9%、75.3%、65.7%。2、另外统计这1990例早期乳腺癌患者总生存情况,3年、5年、7年OS分别为99.1%、96.7%、91.8%。3、对不同分子分型患者预后进行比较,得出LuminalA型的DFS较其他分子分型患者好,其次为LuminalB1、基底样型、LuminalB2,预后最差的为HER-2阳性型。4、LuminalA型、LuminalB1型患者的组织学分级及肿瘤体积较其他分子分型好;HER-2过表达型患者的组织学分级、疾病分期、肿瘤体积较其他分子分型差。结论:1、我中心乳腺癌患者3年、5年、7年OS分别为99.1%,96.7%,91.8%;3年、5年、7年DFS分别为86.9%、75.3%、65.7%,优于国内外相关报道。2、年龄35岁、肿瘤体积大、淋巴结转移数目多、分子分型为HER-2过表达型、基底样型患者肿瘤复发转移风险高,在选择辅助治疗方案时,可给予患者较强的治疗方案。3、存在较高的失访率,部分患者病理资料丢失,有待日后进一步查证与补充,同时改善患者依从性,从而提高结果的准确程度。
[Abstract]:Objective: to collect the basic information, pathological situation, surgical data, treatment course and prognosis of all patients with early breast cancer admitted to the Cancer Center of the first Hospital of Jilin University from January 2007 to December 2016. The changes of patients' condition, the changes of treatment plan and prognosis were analyzed retrospectively. The total DFS and OS were calculated and compared with those at home and abroad. The reasons for the difference were analyzed. The disease characteristics, pathological features and prognosis of patients with different molecular typing were analyzed. At the same time, the disease characteristics of patients with different chemotherapy regimens were compared. Methods: all the patients with early breast cancer were collected from January 2007 to December 2016 in the Cancer Center of the first Hospital of Jilin University. 2465 patients with early breast cancer were included according to the admission criteria. The course of treatment and prognosis were analyzed retrospectively. To understand the difference of onset age, pathological characteristics and prognosis of patients with different molecular types; the disease characteristics of patients receiving different chemotherapy regimens; and the disease characteristics of all patients with recurrence and metastasis. Results: 1, for 1990 patients with complete follow-up data, The DFS for 3, 5, and 7 years were 86.9% and 75.37%, respectively. In addition, the total survival status of 1990 patients with early breast cancer was counted. In 3, 5 and 7 years, the OS was 99.1 96.7% and 91.8% respectively. The prognosis of the patients with different molecular typing was compared, and the results showed that the DFS of LuminalA type was better than that of other molecular typing patients. The histological grade and tumor volume of the patients with HER-2 positive type and LuminalA type B 1 were lower than those of the patients with HER-2 overexpression type, and the histological grade, disease stage and tumor volume of the patients with HER-2 overexpression type were worse than those of other molecular types. Conclusion the OS of the breast cancer patients in the center of our center for 3 years, 5 years, and 7 years is 99.1 96.7 and 91.8, respectively, and the DFS for 3, 5 and 7 years is 86.9% and 75.3% respectively, which is superior to the related reports at home and abroad. The age of 35 years is 35 years, the tumor size is large, the number of lymph node metastasis is more, and the molecular type is HER-2 overexpression. The risk of tumor recurrence and metastasis in patients with basal type is high. In choosing the adjuvant treatment regimen, the patients can be given a strong treatment plan. 3. There is a higher rate of missing visit. Some of the patients' pathological data are lost, which needs further verification and supplement. At the same time, improve the compliance of patients, so as to improve the accuracy of the results.
【学位授予单位】：吉林大学
【学位级别】：硕士
【学位授予年份】：2017
【分类号】：R737.9

【相似文献】